优化伦瓦提尼布治疗以改善晚期甲状腺癌的预后
1Department of Otorhinolaryngology-Head and Neck Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu 807-8555, Fukuoka, Japan.
Pharmaceuticals (Basel, Switzerland)
|October 29, 2025
概括
伦瓦替尼 (LEN) 改善了对放射性耐药差异化甲状腺癌 (RAIR-DTC) 的无进展生存率. 早期启动,剂量管理和毒性控制优化了其在个性化护理中的有效性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗放射性分化甲状腺癌 (RAIR-DTC) 的预后不佳,全身治疗选择有限.
- 伦瓦丁尼布 (LEN) 是一种多位氨酸激酶抑制剂,已成为一种关键的治疗药物.
研究的目的:
- 本叙事综述评估了伦瓦丁尼布 (LEN) 在管理RAIR-DTC中的作用和优化策略.
- 综合证据来提高LEN的有效性和管理其毒性.
主要方法:
- 现有文献的叙述性审查,包括来自SELECT试验的数据和现实世界的证据.
- 分析治疗策略,如早期启动,剂量强度,毒性管理和药物假期.
主要成果:
- 伦瓦提尼布 (LEN) 在RAIR-DTC患者中显著延长了无进展的生存期.
- 优化LEN治疗包括早期启动,保持较高的相对剂量强度,积极的毒性管理和计划的药物假期.
- 新辅助剂LEN可能会在某些无法切除的病例中促进转换手术,剂量调整/再挑战可以恢复疗效.
结论:
- 伦瓦提尼布 (LEN) 是RAIR-DTC的关键治疗方法,通过个性化,多学科的护理和优化的施用策略来最大化益处.
- 需要进一步的前性研究来验证这些优化策略,并评估它们对整体存活率的影响.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


